Adderall XR Cardiovascular Impact Long-Term: What the Evidence Actually Shows

The numbers the Adderall tablet label gives

The Adderall tablet label states that CNS stimulants increase blood pressure by a mean of about 2 to 4 mmHg and heart rate by a mean of about 3 to 6 bpm, that some patients have larger increases, and that all treated patients should be monitored for potential tachycardia and hypertension [2].

These figures come from the immediate-release Adderall tablet label (effective 29 May 2024), where the warning is written for CNS stimulants as a class. Adderall XR is a separate extended-release capsule, approved in 2001 and indicated for ADHD in adults and children aged 6 and older [3].

What the label asks before and during treatment

Before treatment, the Adderall tablet label calls for an assessment for cardiac disease: a careful history, a family history of sudden death or ventricular arrhythmia, and a physical examination [2].

In the 3-week trial of 584 children aged 6 to 12 that tested Adderall XR, vital signs were recorded at each visit, and physical examinations and electrocardiograms were performed at screening and at the end of the study [4].

Warning for people with serious cardiac disease

Sudden death has been reported in patients with structural cardiac abnormalities or other serious cardiac disease who were treated with CNS stimulants at recommended ADHD doses. The tablet label says to avoid Adderall in known structural cardiac abnormalities, cardiomyopathy, serious arrhythmia, coronary artery disease, or other serious cardiac disease [2].

In that label, the instruction sits in the warnings section, not the contraindication list. Its two contraindications are known hypersensitivity to amphetamine or other components, and use of a monoamine oxidase inhibitor, or within 14 days of stopping one [2].

Cardiovascular reactions listed in the tablet label are palpitations, tachycardia, elevation of blood pressure, sudden death and myocardial infarction, plus isolated reports of cardiomyopathy associated with chronic amphetamine use [2].

Overdose is a separate picture: the label describes tachyarrhythmias, hypertension or hypotension, vasospasm, myocardial infarction or aortic dissection that may precipitate sudden cardiac death, and Takotsubo cardiomyopathy [2].

What exists for the long term

Long-term rates of heart attack, stroke and heart failure with Adderall XR are not established by the studies discussed here. The 133-trial analysis of ADHD medications found insufficient data for 26- and 52-week comparisons of ADHD symptom improvement and treatment dropout; it did not address cardiovascular outcomes [1].

A meta-analysis of 93 randomized trials of methylphenidate, lisdexamfetamine and other amphetamines, with trial durations up to 52 weeks, found a higher risk of any adverse event than placebo (risk ratio 1.34, 90% CI 1.27 to 1.41; I2 67%), and the result was significant in the other-amphetamine subgroup as well [5]. That outcome pools every reported adverse event, so it is not a cardiac-specific figure.

For the heart specifically, the tablet label's only chronic-use statement is the line about isolated reports of cardiomyopathy with chronic amphetamine use [2].

Tolerability in trials

In the network meta-analysis, amphetamines (including lisdexamfetamine) had higher dropout from side effects than placebo, both in children and adolescents (odds ratio 2.30, 95% CI 1.36 to 3.89) and in adults (odds ratio 3.26, 95% CI 1.54 to 6.92) [1].

The 4-week trial of Adderall XR in adults randomized 255 people to 20, 40 or 60 mg a day or placebo, and most adverse events were mild or moderate [6].

Interactions listed in the Adderall tablet label

The label contraindicates monoamine oxidase inhibitors with Adderall, or within 14 days of stopping one, including linezolid and intravenous methylene blue, because of hypertensive crisis whose possible outcomes include death, stroke, myocardial infarction, aortic dissection, pulmonary edema and renal failure [2].

Tricyclic antidepressants may produce striking, sustained rises in brain d-amphetamine and potentiate amphetamine's cardiovascular effects, and amphetamines may antagonize the effect of antihypertensives [2].

Gastrointestinal alkalinizing agents such as sodium bicarbonate and antacids raise amphetamine blood levels and potentiate its action; the label says co-administration of Adderall with them should be avoided [2]. Acidifying agents such as ascorbic acid lower blood levels and efficacy [2].